therapeutics

Welcome to the 'therapeutics' tag page at Technorati. This page features content from the farthest reaches of the Blogosphere that authors have "tagged" with 'therapeutics'.

Latest blogosphere posts tagged “therapeutics”

• Point Lippincott Williams & Wilkins: Applied Therapeutics: The Clinical Use of Drugs by Mary Anne Koda-Kimble

  
  Free Your Mind All Free Download — Authority: 161
  Publisher: Lippincott Williams | Pages: 3040 | 2008-08-01 | ISBN 0781765552 | CHM | 40 MB Using a case-based approach, this widely used text helps students develop practical problem-solving skills for devising and implementing successful drug treatment regimens. Case studies integrated into each chapter illustrate ...
  8 hours ago

• Who Will Create the Future of San Diego Biotech? Xconomy Event Will Gather Star Innovators From Inside and Outside the Region

  
  Xconomy — Authority: 708
  Biotech , people , startups Luke Timmerman wrote: Who are the innovators who will help keep the San Diego region’s life sciences sector vibrant in the years to come? Which of the emerging ideas here will help transform the way we treat and prevent disease around the world? And how is the San Diego ...
  8 hours ago

• (RX) Big Pharma and Biotech – Industry Outlook

  
  Stock Blog Hub — Authority: 506
  The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent ...
  21 hours ago

• GEO Monitor IPO Newsflash: Trius Therapeutics Inc

  
  ResearchOracle.com — Authority: 155
  Trius Therapeutics files for NASDAQ listing… If you wish to view the entire report, visit us at GEO Monitor or contact us This report is provided as part of IIR Group Ltd.’s GEO (Global Equity Offerings) Monitor service, which tracks global IPO activity. Our GEO Monitor is the only comprehensive research ...
  1 day ago

• Good Things in Threes: Trius Therapeutics Files for IPO to Fund Phase 3 Clinical Trials, Marks San Diego’s Third IPO Filing

  
  Xconomy — Authority: 708
  IPO , Drug-Resistant Infections , Drug Development Bruce V. Bigelow wrote: San Diego’s Trius Therapeutics , a venture-backed biotech developing a new antibiotic for treating acute and life-threatening bacterial infections, submitted a regulatory filing Friday to raise as much as $86 million in an ...
  1 day ago

• Trius Therapeutics Files For IPO

  
  socalTECH.com - Southern California High Tech News — Authority: 561
  San Diego-based Trius Therapeutics has filed for an IPO, saying Friday that it is looking to raise $86.25M in an offering on the Nasdaq Global Market. According to the firms filing, it has applied to trade under the symbol TSRX. The IPO is being underwritten by Credit Suisse, Piper Jaffray, Canaccord Adams, and JMP ...
  1 day ago

• AACR, NCI and EORTC to host Molecular Targets and Cancer Therape...

  
  Health Fitness & Beauty - health-fitness.marc8.com — Authority: 158
  (American Association for Cancer Research) Scientists and industry leaders from around the world will gather in Boston Nov. 14-19, 2009, for the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International Conference, which will feature groundbreaking information on important cancer therapies in development.
  1 day ago

• (ACOR) Acorda Therapeutics – Bull of the Day

  
  Stock Blog Hub — Authority: 506
  Acorda Therapeutics ( ACOR ) is one of the more interesting biotechnology companies under our coverage. The company’s key pipeline drug, Fampridine-SR, is currently under U.S. FDA review, with a decision expected in late January 2010. Outside the U.S., Acorda has partnered with Biogen Idec under very favorable ...
  1 day ago

• ProtoxPresents Data, Awaits Key Results for PRX302

  
  OneMedPlace — Authority: 123
  By Mike Havrx ProActive Newsroom Protox Therapeutics (TSX: PRX.TO) (OTC: PTXRF.PK) applies genetic engineering techniques to create innovative, targeted protein-based therapeutics which are focused on prostate conditions and cancer. The Company’s clinical-stage pipeline is based on the PORxin and INxin ...
  2 days ago

• ($KG) King Pharmaceuticals Beats Consensus, but Earnings Down

  
  Stock Blog Hub — Authority: 506
  King Pharmaceuticals, Inc. ( KG ) reported third quarter earnings of 29 cents per share, beating the Zacks Consensus Estimate by 2 cents. Despite revenues increasing 19.3% from the year-ago period, earnings declined 25.6% from the year-ago quarter mainly due to higher operating expenses. Total revenues came in at ...
  2 days ago

• Guided Therapeutics Study Reveals Cervical Screening Shortcomings

  
  OneMedPlace — Authority: 123
  A multi-center clinical trial by Guided Therapeutics  (GT), a biotechnology company specializing in women’s health, found that current screening methods for cervical disease  failed  nearly a third of the time. The findings are similar to the results of an earlier landmark study carried out by the National ...
  3 days ago

• Durezol

  
  AdPharm Blog — Authority: 141
  Click here to see the original post on AdPharm Visit AdPharm.net for more pharmaceutical ads
  4 days ago

• A Resurgence for Gene Therapy

  
  Newsvine - JCAtom's Column - Articles and Seeds — Authority: 125
  scientists say gene therapy may be on the edge of a resurgence.
  4 days ago

• GenVec Receives Orphan Drug Designation, $22M Development Deal

  
  OneMedPlace — Authority: 123
  GenVec ’s experimental drug to treat pancreatic cancer has been granted orphan drug status by the U.S. Food and Drug Administration (FDA).  The drug candidate TNFerade stimulates the production of an immune system protein known for having anti-cancer effects.  Shares in GenVec rose 25 percent following the ...
  4 days ago

• Community News (V11-I46)

  
  Muslim Media Network — Authority: 435
  Ruhi Khan named VP of Acorda Therapeutics HAWTHORNE, NY–Ruhi Khan recently named Vice President, Business Development, of Acorda Therapeutics reporting to President and CEO RonCohen, M.D. Previously, Ms. Khan was the Executive Director, Business Development at Acorda. Before joining the Company, Ms. Khan was the ...
  4 days ago

• Build it Boldly, and Pharma Will Come—and More Wisdom from Boston’s Biotech and Pharma Elite at Xconomy Forum

  
  Xconomy — Authority: 708
  Life Sciences , innovation , Xconomy Forum Ryan McBride wrote: It was an inspiring afternoon yesterday at Xconomy’s latest event, “Pharma’s Bet on Boston Innovation,” in Cambridge, MA. Local industry pioneers such as Millennium CEO Deborah Dunsire and Sirtris CEO Christoph Westphal talked about ...
  5 days ago

• BioMimetic Therapeutics Receives First Orthopedic Marketing Approval For Augment™ Bone Graft

  
  emedist.com — Authority: 159
  BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) announced today that it has received approval from Health Canada to begin the marketing of its lead orthopedic product, Augment™ Bone Graft, as an alternative [...]
  5 days ago

• (ALTH) Allos Therapeutics Reports Earnings in Line

  
  Stock Blog Hub — Authority: 506
  Allos Therapeutics ’ ( ALTH ) third quarter loss per share came in at 21 cents, in line with the Zacks Consensus Estimate. However, the loss increased compared to the net loss of 16 cents reported in the year ago period. Loss increased primarily due to a 41% rise in operating expense. The huge increase in general ...
  5 days ago

• Gene Therapy Restores Sight

  
  Newsvine - JCAtom's Column - Articles and Seeds — Authority: 125
  The boy relied on a cane and adults to guide him, and, unable to see blackboard writing, sat in back with a teachers aide, large-type computer screen and materials in Braille.
  1 week ago

• (UTHR) United Therapeutics Corporation Misses Earnings Estimates

  
  Stock Blog Hub — Authority: 506
  United Therapeutics Corporation ( UTHR ) reported a net income of 21 cents per share in the third quarter, well below the Zacks Consensus Estimate of 31 cents. The company reported earnings of 22 cents in the year-ago period. Even though revenues increased 29.6% to $97.2 million in the reported quarter, higher ...
  1 week ago

Comments about therapeutics